Table 3 Model evaluation for neuroendocrine prostate cancer.
Category | Test items | Rules |
|---|---|---|
Cell model | Morphology | Neuron-like cell bodies and processes: 1 point multicellular spherical aggregates: 1 point |
Phenotype (Molecular markers) | SYP/CGA/NSE/CD56/β-tubulin3 positive: 2 points PSA negative: 2 points AR weakened or negative: 1 point | |
Molecular biology and genomics | NEPC-related gene expression changes: 4 points | |
Cell dynamics and biological functions | Slow proliferation; anti-apoptosis: 1 point No response to ARPI, platinum-sensitive: 1 point | |
Animal model | Oncology | No response to androgen deprivation: 1 point |
Histopathology | Small cell morphology, high nuclear to mass ratio, “salt and pepper” like chromatin/large cell morphology, extensive necrosis: 2 points | |
Hematology and molecular markers | Serum PSA normal/SYP, cga increased: 1 point SYP/CGA/NSE/CD56/β-tublin3 positive: 2 points PSA negative: 1 point AR weakened or negative: 1 point | |
Molecular biology and genomics | NEPC-related gene expression changes: 4 points | |
Cell dynamics and biological functions | Fast proliferation; anti-apoptosis; strong invasion ability; metastasis: 1 point ARPI treatment resistance, platinum sensitivity: 1 point |
